Randomized Comparison of MynxGrip Vascular Closure Device and Manual Compression for Closure After Femoral Access Angiography. The Closure Devices Used in Every Day Practice Study, CLOSE-UP III Trial
- Conditions
- Coronary Disease
- Registration Number
- NCT02237430
- Lead Sponsor
- Aarhus University Hospital Skejby
- Brief Summary
Is the MynxGrip (test device) non-inferior to manuel compression (standard comparator) in the incidence of adverse access site related events in-hospital, at 30 days and at 6 months.
- Detailed Description
Prospective, randomized (1:1), controlled, non-blinded, single center study in 2000 patients comparing the MynxGrip (test device) and manuel compression (standard comparator). Safety and efficacy endpoints will be reported for in-hospital, 30 days and 6 months.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 869
- >18 year
- Should be able to provide valid informed signed consent
- CAG, possibly including intracoronary measurement (FFR) or intracoronary imaging (IVUS, optical coherence tomography (OCT), NIRS)
- Percutaneous coronary intervention (PCI) procedure and/or implantation of stents
- ST-Elevations Myocardial Infarction (STEMI)
- Multiple punctures
- Active infection
- Groin haematoma before the closure procedure
- Known pseudoaneurysm or arteriovenous (AV) fistula in the ipsilateral groin
- Cardiogenic shock
- Prior peripheral arterial surgery in abdomen or lower extremities
- Sheat size >7 F
- Life expectancy less than one year
- Possible pregnancy or positive pregnancy test or breastfeeding women
- Simultaneous or planned subsequent femoral vein access
- Allergy to any of the components in the closure material left in the groin
- Puncture or closure with closure device at same site < 30 days
- Puncture or closure with manuel compression at same site < 5 days
- Patients with peripheral artery disease can be included at operators discretion except if heavy calcification is present at the access site, which at the operators discretion precludes insertion of the closure device
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Incidence at 30 days of the composite endpoint of serious access site related major adverse vascular events (MAVE) 30 days This includes: Major bleeding and/or blood transfusion, pseudoaneurysm with indication for treatment, arteriovenous fistula, groin surgery of leg, definitely or possible can be related to the closure procedure, infection needing antibiotics.
- Secondary Outcome Measures
Name Time Method Need for medical evaluation of possible closure procedure related symptom(s) 30 days Pain and discomfort related to the closure procedure Closure procedure and 30 days Assessed on a numerical rating scale (NRS) from 0 (no pain or discomfort) to 10 (worst possible pain or discomfort).
Time to mobilization participants will be followed for the duration of hospital stay, an expected average of 2 days From start of closure procedure to patient is mobilised.
Bleedings according to the Bleeding Academic Research Consortium (BARC) definitions 1 hour and 30 days Major bleeding and/or bleeding necessitation blood transfusion 30 days and 6 months Pseudoaneurysm with indication for treatment 30 days and 6 months Arteriovenous fistula 30 days and 6 months Vasovagal reaction until 5 minutes after end of closure procedure 30 minutes Time (min) to haemostasis 30 days From inserting the device (MynxGrip) until haemostasis and from beginning of manual compression to immediately haemostasis
In-hospital large groin haematoma Participants will be followed for the duration of hospital stay, an expected average of 2 days Larger than 5 x 5 cm measured by ruler in the catheterisation laboratory or at discharge
Groin surgery and/or possible related vascular surgery 30 days and 6 months Device failure 30 minutes Need for new onset of manual compression 30 days Infection needing antibiotics 30 days and 6 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Aarhus University Hospital
🇩🇰Aarhus N, Denmark
Aarhus University Hospital🇩🇰Aarhus N, Denmark